KAE609A2202

November 02, 2020 | News | Reading time: 3 min

KAE609A2202 - Kintampo Health Research Centre HomeNews & UpdatesKAE609A2202 This was a phase IIb multicentre, randomized, dose-escalation trial to determine the safety of a novel anti-malarial compound (KAE609) developed by Novartis Pharma AG. KHRC recruited 23 adult patients with uncomplicated falciparum malaria. Participants were randomized to receive different doses of orally administered KAE609 or Coartem (comparator) and followed up for 28 days for clinical and laboratory safety assessments. KAE609 was well tolerated. The number and type of adverse events recorded were similar between the treatment and comparator arms. Common adverse events included headache and diarrhoea, which were mild and self-limiting. In conclusion, KAE609 was safe and well-tolerated when administered to adults patients with uncomplicated falciparum malaria.

Details can be found in the link below
https://www.astmh.org/ASTMH/media/2019-Annual-Meeting/ASTMH-2019-Abstract-Book.pdf